Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06109051 · ClinicalTrials.gov registry record
EndeavorOTC™ Prospective Product Registry
A clinical trial of ADHD, sponsored by Akili Interactive Labs.
- Active
- Registry status
- 198
- Enrollment target
- 1
- Study location
NCT06109051: Active study of ADHD, sponsored by Akili Interactive Labs.
NCT06109051 is a study of ADHD that is active but no longer recruiting, run by Akili Interactive Labs. The registered enrollment target is 198 participants, roughly in line with the 188-participant average among 75 other ADHD trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06109051, a study of ADHD, is active but no longer recruiting, sponsored by Akili Interactive Labs.
- ACTIVE NOT RECRUITING
- Registry status
- 198 participants
- Enrollment target
- 1
- Study location
Study Summary
The EndeavorOTC product registry aims to collect real world data from EndeavorOTC users. The objectives of this registry are to describe clinical and demographic characteristics, treatment patterns, clinical and quality of life outcomes, and healthcare utilization in EndeavorOTC users in a real-world setting.
Primary Outcome
Computerized Adaptive Test, Mental Health (CAT-MH®) is a distinct suite of computer adaptive tests that is based on multidimensional item response theory. The adult ADHD module is a dimensional severity measure of attention-deficit/hyperactivity disorder symptomatology for adults 18 and over. The number and selection of questions within the assessment varies as individuals' initial item responses are used to determine a provisional estimate of their standing on the measured trait to be used for
Conditions Studied
Interventions
- DEVICE EndeavorOTC
Study Locations (1)
Massachusetts
- Akili Interactive Labs, Inc. - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 198 participants |
| Start Date | 2023-10-03 |
| Est. Completion | 2026-12-31 |
What the registry record for NCT06109051 still lists
NCT06109051 is an observational study that tracks outcomes without assigning an intervention. The registered 198 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 188-participant average among 75 other ADHD trials with a reported enrollment target.
The record links to 1 condition, with ADHD appearing as the primary indexed condition, and to 1 intervention - of which EndeavorOTC is the first listed.
NCT06109051 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06109051 about?
NCT06109051 is a clinical study titled "EndeavorOTC™ Prospective Product Registry". The EndeavorOTC product registry aims to collect real world data from EndeavorOTC users. The objectives of this registry are to describe clinical and demographic characteristics, treatment patterns, clinical and quality of life outcomes, and healthcare utilization in EndeavorOTC users in a real-worl...
What is the current status of trial NCT06109051?
This trial is currently active not recruiting. The enrollment target is 198 participants. The study started on 2023-10-03. Estimated completion is 2026-12-31.
What conditions does trial NCT06109051 study?
This clinical trial studies the following conditions: ADHD.
What interventions are being tested in trial NCT06109051?
The interventions under investigation include: EndeavorOTC (DEVICE).
Who is sponsoring clinical trial NCT06109051?
This trial is sponsored by Akili Interactive Labs, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06109051 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ADHD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06109051's enrollment target sits among peer trials
198 22nd of 75 higher than 54 of 75 other ADHD trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other ADHD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Comparative Efficacy of Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI)
RECRUITING · NA
-
Target ADHD Executive Working Memory Replication Study
RECRUITING · NA
-
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
RECRUITING · Phase 4
-
Comparative Efficacy of Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI)
RECRUITING · NA
-
Evaluating Treatment of ADHD in Children with Down Syndrome
RECRUITING · Phase 4
-
Fidgeting and Attentional and Emotional Regulation in ADHD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05203328 · 198 participants · NA
Prospective Study to Evaluate High Flow Nasal Cannula With Monitored Anesthesia Care During EBUS Bronchoscopy
- NCT05426967 · 198 participants · NA
rTMS for Military TBI-related Depression
- NCT05561114 · 198 participants · Phase 3
Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophagus
- NCT05585190 · 198 participants · NA
Stand Up for Your Health with a Sit-stand Desk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI